Ziwei Chen

Ziwei Chen

Auto-generated profile, based on publicly available information

Ziwei Chen

Department of Pediatrics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2023 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
ZCZiwei Chen
Ziwei Chen
QYQing You
Qing You
JWJunqi Wang
Junqi Wang
ZDZhiya Dong
Zhiya Dong
WWWei Wang
Wei Wang
WLWenli Lu
Wenli Lu

1 January 2025 in International Journal of Endocrinology
Verified
Journal Article
Open access
ZCZiwei Chen
Ziwei Chen
WLWenying Li
Wenying Li
JWJunqi Wang
Junqi Wang
ZDZhiya Dong
Zhiya Dong
CLChuanyin Li
Chuanyin Li
WLWenli Lu
Wenli Lu
Objective: To assess the therapeutic effects of gonadotropin‐releasing hormone agonist (GnRHa) on children with familial central precocious puberty (FCPP) due to Makorin ring finger Protein 3 ( MKRN3 ) gene mutations. Methods: Children with central precocious puberty (CPP) who were admitted to the Pediatric Endocrinology Department of Shanghai Ruijin Hospital from 2014 to 2021 were enrolled, of whom 4 FCPP children with MKRN3 gene mutations, including 3 girls and 1 boy, were selected as research subjects. Their height, weight, body mass index (BMI), predicted adult height (PAH), bone age, bone age advance (BAA, bone age minus chronological age), height‐based standard deviation scores (Ht‐SDS) corresponding to the chronological age, concentrations of sex hormones (luteinizing hormone [LH] and follicle‐stimulating hormone [FSH]), and development of sexual organs were compared before and after at least 2 years of GnRHa treatment. Results: After at least 2‐year GnRHa treatment, mean volume of uterus of three girls decreased from 5.72 ± 2.58 to 2.12 ± 1.62 mL ( p < 0.05) and mean volume of ovaries decreased from 3.61 ± 1.67 to 0.62 ± 0.22 mL ( p < 0.05) as well, indicating that the gonadal development was effectively inhibited. Basal concentrations of LH and FSH in serum decreased, indicating that the secretion of gonadotropin in the anterior pituitary is inhibited. BAA and Ht‐SDS decreased, suggesting that the bone age was restrained, and the growth rate was slowed down to some extent. Both average BMI and obesity prevalence ( X 2 = 7.188, p = 0.029) decreased during the treatment. No obvious adverse reaction was found. Conclusion: Long‐term GnRHa treatment could effectively inhibit the gonadal development and FSH secretion in FCPP children with MKRN3 gene mutations, while this inhibitory effect on the bone age and growth rate was not obvious. Adverse reactions such as increased prevalence of obesity were not found. A large‐scale, long‐term follow‐up study is required to indicate whether patients’ final height (FH) could reach PAH or target height (TH).